Current RRMS Disease Modifying Treatments (DMTs) include low risk drugs with modest effectiveness, and high risk drugs with substantial therapeutic effects. New higher risk treatment options can be desirable for improving convenience and diminishing side effects.

 

However, as with any immunosuppressive treatment, these high risks can include potential infection and cancer, and long-term safety may still need to be ascertained. Because of the potential for increased risks,  some high risk drugs are recommended as first line treatments only in the USA, and as second line treatments elsewhere.

 

The gMS® DMT approach will help physicians optimize treatment regimens for patients resulting in either better outcomes, and/or reduced costs by identifying which patients will likely respond best to more aggressive treatments. Studies currently underway will reveal whether the anti-glycan antibody profile (AGAP) can be used to predict and monitor high risk drug-treated patients for risk of infection and neoplasms. The detection of RRMS patients at risk for infection will increase the safety of these treatments and allow their prescription to suitable patients.

 

We are continuing our research in this area and invite Healthcare providers and Pharmaceutical companies to join our efforts.